| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/24/2005 | WO2004050072A8 Water-soluble composition containing coenzyme q10 |
| 03/24/2005 | WO2004047768A3 Buoyant polymer particles delivering therapeutic agents |
| 03/24/2005 | WO2004024777A8 Hydroxyalkyl starch derivatives |
| 03/24/2005 | WO2004000197A3 Quick dissolve compositions and tablets based thereon |
| 03/24/2005 | WO2003077861A3 Water-based delivery systems |
| 03/24/2005 | WO2003045973A8 Peptides with growth inhibitory action |
| 03/24/2005 | US20050065335 inhibiting complexation of intercalating molecules with polynucleotides; using modified xanthine molecules as a binding agent; drug delivery system for compounds that have low solubility in aqueous media, including anti-neoplastic agents |
| 03/24/2005 | US20050065281 Use of biomaterials which act as three dimensional scaffolds or matrices (with or without bioactive factors attached) for wound healing applications and tissue regeneration |
| 03/24/2005 | US20050065183 Bioavailability; mixture containing lactose and hydroxypropyl cellulose |
| 03/24/2005 | US20050065113 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments |
| 03/24/2005 | US20050065107 Plasmids suitable for IL-2 expression |
| 03/24/2005 | US20050065086 Adjust drug releasing characteristics, bioavailability of oral drug |
| 03/24/2005 | US20050065075 Viricides; respiratory synctia virus; parainfluenza virus; simian immunodeficiency virus; complexing drug to blood component; immobilization; storage stability |
| 03/24/2005 | US20050064596 Buffer solution for electroporation and a method comprising the use of the same |
| 03/24/2005 | US20050064518 Monoclonal antibody for use in prevention and treatment of ovarian cancer; immunotherapeutics |
| 03/24/2005 | US20050064492 Compositions and methods for the diagnosis and treatment of tumor |
| 03/24/2005 | US20050064460 Emulsion compositions |
| 03/24/2005 | US20050064045 Chemical ablation agent to cause tissue necrosis, and a biodegradable viscosity agent to form a highly viscous formulation for injection; prostatic ablation to treat benign prostatic hyperplasia |
| 03/24/2005 | US20050064038 Two or more active agents (drugs) in a layer of a miscible polymer blend where delivery of one active agent occurs faster due to its greater permeability than the other drugs; medical devices such as stents; versatility in mechanical properties, active agents |
| 03/24/2005 | US20050064037 Transdermal delivery of oxybutynin in gel formulations |
| 03/24/2005 | US20050064028 Pharmaceutical compositions containing plasma protein |
| 03/24/2005 | US20050064027 Prolonged gastric retention time due to bioadhesion (which may be polymers, metal oxides, or ligands for specific mucosal components); macrospheres for delivery of acyclovir for example |
| 03/24/2005 | US20050064025 With a phospholipid such as dipalmitoyl phosphatidylcholine, and an antiinflammatory drug such as a nonsteroidal, anti-inflammatory drug (NSAID) such as celecoxib |
| 03/24/2005 | US20050064023 Lipid linked to a delivery, targeting or stabilising moiety (DTS moiety) via a linker which is stable in biological fluid and which is unstable in defined conditions, forms a complex with a therapeutic agent; for non-viral gene transfer |
| 03/24/2005 | US20050064017 feeding dog or cat the pet food including 5-40% by weight protein, 5-45% by weight fat, 0.1 to 12% by weight fiber, 1 to 90% by weight digestible carbohydrate, 0.1-2% by weight functional ingredient to build lean muscle mass |
| 03/24/2005 | US20050063998 completely dissolving galantamine or salt , intense sweetener, in a bulk liquid carrier to form a solution, diluting the solution with purified wate; Alzheimer disease and related dementia, mild cognitive impairment (MCI), Lewy body disease (LBD), Parkinson disease, schizophrenia |
| 03/24/2005 | US20050063951 Function of a haptoglobin-haemoglobin receptor and the uses thereof |
| 03/24/2005 | US20050063950 Cell-targeting ligand (e.g. transferrin) noncovalently bound directly to a virus; less inactivation of ligand than with conjugation; tissue targeted therapy; sensitizing cancer cells prior to chemotherapy or radiotherapy |
| 03/24/2005 | US20050063948 Methods for targeting interleukin-12 to malignant endothelium |
| 03/24/2005 | US20050063943 Conjugated of hydroxyalkyl starch and an active agent |
| 03/24/2005 | US20050063941 Biodegradable polymeric material for biomedical applications |
| 03/24/2005 | US20050063940 Use of (poly)ethoxylated fatty acid glycerides for enhancing bioadhesion of a liquid pharmaceutical applied to a mucous membrane; use delivering active agents to plants, fish gills |
| 03/24/2005 | US20050063937 Multiple-arm peptide compounds, methods of manufacture and use in therapy |
| 03/24/2005 | US20050063936 Branched polyalkylene glycols |
| 03/24/2005 | US20050063930 Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance |
| 03/24/2005 | US20050063926 Comprises polyetherurethanes and nitrocellulose dispersed in carrier containing tackifier resin (polyterpene); for barrier teat dips, protecting cows against mastitis, especially during non-lactating periods |
| 03/24/2005 | US20050063917 Solid oral compositions |
| 03/24/2005 | US20050063902 Stabiliser for radiopharmaceuticals |
| 03/24/2005 | US20050061678 Treatment of humans with colloidal silver composition |
| 03/24/2005 | US20050061314 Metered dose inhaler |
| 03/24/2005 | DE10339197A1 Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität Spray-dried amorphous powder having a low residual moisture content and good storage stability |
| 03/24/2005 | CA2551022A1 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 03/24/2005 | CA2538755A1 Granular jelly drink capable of masking bitterness |
| 03/24/2005 | CA2538754A1 Inhibition of inward sodium currents in cancer |
| 03/24/2005 | CA2538395A1 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 03/24/2005 | CA2538237A1 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| 03/24/2005 | CA2537820A1 Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins |
| 03/24/2005 | CA2537250A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 03/24/2005 | CA2535373A1 Methods for the controlled delivery of pharmacologically active compounds |
| 03/24/2005 | CA2533926A1 Methods and compositions for producing antigenic responses |
| 03/24/2005 | CA2504885A1 Agent containing ergolin for transdermal application |
| 03/23/2005 | EP1516932A1 Poxvirus with targeted infection specificity |
| 03/23/2005 | EP1516631A1 Body ointment having decongestant effect and for the progressive relief of muscular pain, sprains, wrenchs, dislocations, aches and for relief of articular and rheumatic pain |
| 03/23/2005 | EP1516622A1 Stable diltiazem hydrochloride pharmaceutical composition for cutaneous application and process for the preparation thereof |
| 03/23/2005 | EP1516616A1 A controlled-release preparation having specific pore forming agents in the coating |
| 03/23/2005 | EP1516615A2 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| 03/23/2005 | EP1516283A1 Actuation indicator for a dispensing device |
| 03/23/2005 | EP1516185A2 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 03/23/2005 | EP1516064A2 Methods of using 46828, a human acyl-coa synthetase |
| 03/23/2005 | EP1516058A2 Recombinant measles viruses expressing epitopes of antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions |
| 03/23/2005 | EP1515989A1 Immunogenic conjugates |
| 03/23/2005 | EP1515974A2 Novel maxi-k channel blockers, methods of use and process for making the same |
| 03/23/2005 | EP1515775A2 Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
| 03/23/2005 | EP1515766A1 Method and packaging for pressurized containers |
| 03/23/2005 | EP1515751A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 03/23/2005 | EP1515744A2 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| 03/23/2005 | EP1515741A1 Composition comprising viscous fibers and viscosity-lowering proteins |
| 03/23/2005 | EP1515740A1 Aqueous preparation containing oligopeptides and etherified cyclodextrin |
| 03/23/2005 | EP1515734A1 Honey-based skin care preparation |
| 03/23/2005 | EP1515728A2 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema |
| 03/23/2005 | EP1515722A2 Ophthalmic compositions for treating ocular hypertension |
| 03/23/2005 | EP1515721A1 Ophthalmic compositions for treating ocular hypertension |
| 03/23/2005 | EP1515710A1 Method of treating rosacea by topical application of a cyclohexane derivative |
| 03/23/2005 | EP1515706A2 A platform for transdermal formulations (ptf) |
| 03/23/2005 | EP1515705A1 Fluorosiloxane matrix controlled diffusion drug delivery system |
| 03/23/2005 | EP1515704A1 Microcapsules for the delayed, controlled release of perindopril |
| 03/23/2005 | EP1515703A1 Pharmaceutical compositions with improved dissolution |
| 03/23/2005 | EP1515702A1 Abuse-protected administration form |
| 03/23/2005 | EP1515698A2 Liposomes containing biologically active compounds |
| 03/23/2005 | EP1515697A1 Short duration depot formulations |
| 03/23/2005 | EP1515690A2 Breath freshening and oral cleansing product with magnolia bark extract |
| 03/23/2005 | EP1515682A1 Biliquid foam entrapment |
| 03/23/2005 | EP1515618A1 Nano-sized self-assembled structured liquids |
| 03/23/2005 | EP1515607A2 Antimicrobial compositions, products and methods employing same |
| 03/23/2005 | EP1357937B1 Use of botuline toxin to obtain a product to be used in articular pathologies, particularly coxarthrosis, epicondylitis and rotator muscle cap pathology |
| 03/23/2005 | EP1343542B1 Carrier with solid fibrinogen and solid thrombin |
| 03/23/2005 | EP1335728B1 Medicament compositions based on tiotropium salts and on salmeterol salts |
| 03/23/2005 | EP1322595A4 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 03/23/2005 | EP1311285B1 Liquid pharmaceutical composition containing an erythropoietin derivative |
| 03/23/2005 | EP1235566B1 Injectable valnemulin formulation |
| 03/23/2005 | EP1231901A4 Edible coating composition |
| 03/23/2005 | EP1100469B1 Rapidly disintegrable solid preparation |
| 03/23/2005 | EP0973886B1 Method and conjugate for treating helicobacter pylori infections |
| 03/23/2005 | EP0723398B1 Superoxide dismutase mimetics |
| 03/23/2005 | CN1599752A Nucleic protein 'Shoca'-a component of wnt signal transmission channel |
| 03/23/2005 | CN1599745A Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist |
| 03/23/2005 | CN1599715A Venlafaxine hydrochloride monohydrate and methods for the preparation thereof |
| 03/23/2005 | CN1599627A Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| 03/23/2005 | CN1599626A Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 03/23/2005 | CN1599620A Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and prod |